G.M. Chertow, G.A. Block, R. Correa-Rotter, T.B. Drueke, J. Floege, and W.G. Goodman Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis N Engl J Med 367 2012 2482 2494
V. Perkovic, and B. Neal Trials in kidney disease: time to EVOLVE N Engl J Med 367 2012 2541 2542
G.A. Block, D. Zaun, G. Smits, M. Persky, S. Brillhart, and K. Nieman Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients Kidney Int 78 2010 578 589
J. Cunningham, M. Danese, K. Olson, P. Klassen, and G.M. Chertow Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism Kidney Int 68 2005 1793 1800
P. Raggi, G.M. Chertow, P.U. Torres, B. Csiky, A. Naso, and K. Nossuli The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis Nephrol Dial Transplant 26 2011 1327 1339
T. Adragao, A. Pires, R. Birne, J.D. Curto, C. Lucas, and M. Goncalves A plain X-ray vascular calcification score is associated with arterial stiffness and mortality in dialysis patients Nephrol Dial Transplant 24 2009 997 1002
G.M. Chertow, S.K. Burke, and P. Raggi Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients Kidney Int 62 2002 245 252
A.P. Guerin, G.M. London, S.J. Marchais, and F. Metivier Arterial stiffening and vascular calcifications in end-stage renal disease Nephrol Dial Transplant 15 2000 1014 1021
G. Jean, E. Bresson, J.C. Terrat, T. Vanel, J.M. Hurot, and C. Lorriaux Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences Nephrol Dial Transplant 24 2009 948 955
G.M. London, A.P. Guerin, S.J. Marchais, F. Metivier, B. Pannier, and H. Adda Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality Nephrol Dial Transplant 18 2003 1731 1740
G.M. London, S.J. Marchais, A.P. Guerin, P. Boutouyrie, F. Metivier, and M.C. de Vernejoul Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD J Am Soc Nephrol 19 2008 1827 1835
M.K. Sigrist, M.W. Taal, P. Bungay, and C.W. McIntyre Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease Clin J Am Soc Nephrol 2 2007 1241 1248
J.A. Barman Balfour, and L.J. Scott Cinacalcet hydrochloride Drugs 65 2005 271 281
G.A. Block, K.J. Martin, A.L. de Francisco, S.A. Turner, M.M. Avram, and M.G. Suranyi Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis N Engl J Med 350 2004 1516 1525
S. Fishbane, W.B. Shapiro, D.B. Corry, S.L. Vicks, M. Roppolo, and K. Rappaport Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results Clin J Am Soc Nephrol 3 2008 1718 1725
W.G. Goodman, G.A. Hladik, S.A. Turner, P.W. Blaisdell, D.A. Goodkin, and W. Liu The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism J Am Soc Nephrol 13 2002 1017 1024
E.F. Nemeth, W.H. Heaton, M. Miller, J. Fox, M.F. Balandrin, and B.C. Van Wagenen Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl J Pharmacol Exp Ther 308 2004 627 635
A.L. de Francisco, M. Izquierdo, J. Cunningham, C. Pinera, R. Palomar, and G.F. Fresnedo Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet Nephrol Dial Transplant 23 2008 2895 2901
C. Valle, M. Rodriguez, R. Santamaria, Y. Almaden, M.E. Rodriguez, and S. Canadillas Cinacalcet reduces the set-point of the PTH-calcium curve J Am Soc Nephrol 19 2008 2430 2436
M. Ketteler, K.J. Martin, M. Wolf, M. Amdahl, M. Cozzolino, and D. Goldsmith Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study Nephrol Dial Transplant 27 2012 3270 3278
J. Floege, P. Raggi, G.A. Block, P.U. Torres, B. Csiky, and A. Naso Study design and subject baseline characteristics in the ADVANCE study: effects of cinacalcet on vascular calcification in haemodialysis patients Nephrol Dial Transplant 25 2010 1916 1923
C. Gauci, O. Moranne, B. Fouqueray, R. de la Faille, G. Maruani, and J.P. Haymann Pitfalls of measuring total blood calcium in patients with CKD J Am Soc Nephrol 19 2008 1592 1598
I. Shahapuni, J. Mansour, L. Harbouche, B. Maouad, M. Benyahia, and K. Rahmouni How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients? Semin Dial 18 2005 226 238
P. Urena, S.H. Jacobson, E. Zitt, M. Vervloet, F. Malberti, and N. Ashman Cinacalcet and achievement of the NKF/K-DOQI™ recommended target values for bone and mineral metabolism in real-world clinical practice: the ECHO observational study Nephrol Dial Transplant 24 2009 2852 2859
W.L. St Peter, Q. Li, J. Liu, M. Persky, K. Nieman, and C. Arko Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006 Clin J Am Soc Nephrol 4 2009 354 360
P.A. Urena-Torres, J. Floege, C.M. Hawley, E. Pedagogos, W.G. Goodman, and F. Petavy Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study Nephrol Dial Transplant 28 5 2013 1241 1254
D.A. Bushinsky Clinical application of calcium modeling in patients with chronic kidney disease Nephrol Dial Transplant 27 2012 10 13
D.A. Bushinsky Contribution of intestine, bone, kidney, and dialysis to extracellular fluid calcium content Clin J Am Soc Nephrol 5 Suppl. 1 2010 S12 S22
P. Houillier Pourquoi la calcémie et le bilan de calcium sont-ils indépendants ? Nephrol Ther 8 2012 557 560
A. Bas, I. Lopez, J. Perez, M. Rodriguez, and E. Aguilera-Tejero Reversibility of calcitriol-induced medial artery calcification in rats with intact renal function J Bone Miner Res 21 2006 484 490
P. Evenepoel, L. Viaene, and B. Meijers Calcium balance in chronic kidney disease: walking the tightrope Kidney Int 81 2012 1057 1059
D.J. Goldsmith, A. Covic, P.A. Sambrook, and P. Ackrill Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis Nephron 77 1997 37 43
C. Henley, M. Colloton, R.C. Cattley, E. Shatzen, D.A. Towler, and D. Lacey 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism Nephrol Dial Transplant 20 2005 1370 1377
W.G. Goodman, J. Goldin, B.D. Kuizon, C. Yoon, B. Gales, and D. Sider Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis N Engl J Med 342 2000 1478 1483
J. Oh, R. Wunsch, M. Turzer, M. Bahner, P. Raggi, and U. Querfeld Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure Circulation 106 2002 100 105
M. Hayashi, Y. Tsuchiya, Y. Itaya, T. Takenaka, K. Kobayashi, and M. Yoshizawa Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial Nephrol Dial Transplant 19 2004 2067 2073
M. Teng, M. Wolf, E. Lowrie, N. Ofsthun, J.M. Lazarus, and R. Thadhani Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy N Engl J Med 349 2003 446 456
R. Narayan, R.M. Perkins, E.P. Berbano, C.M. Yuan, R.T. Neff, and E.S. Sawyers Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis Am J Kidney Dis 49 2007 801 813
A. Kramer, V. Stel, C. Zoccali, J. Heaf, D. Ansell, and C. Gronhagen-Riska An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006 Nephrol Dial Transplant 24 2009 3557 3566
W.N. Suki, R. Zabaneh, J.L. Cangiano, J. Reed, D. Fischer, and L. Garrett Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients Kidney Int 72 2007 1130 1137
E. Hagstrom, E. Ingelsson, J. Sundstrom, P. Hellman, T.E. Larsson, and L. Berglund Plasma parathyroid hormone and risk of congestive heart failure in the community Eur J Heart Fail 12 2010 1186 1192
A. Besarab, W.K. Bolton, J.K. Browne, J.C. Egrie, A.R. Nissenson, and D.M. Okamoto The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 1998 584 590
G. Eknoyan, G.J. Beck, A.K. Cheung, J.T. Daugirdas, T. Greene, and J.W. Kusek Effect of dialysis dose and membrane flux in maintenance hemodialysis N Engl J Med 347 2002 2010 2019
C. Wanner, V. Krane, W. Marz, M. Olschewski, J.F. Mann, and G. Ruf Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 2005 238 248
B.C. Fellstrom, A.G. Jardine, R.E. Schmieder, H. Holdaas, K. Bannister, and J. Beutler Rosuvastatin and cardiovascular events in patients undergoing hemodialysis N Engl J Med 360 2009 1395 1407
